– USA, MA – Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, announced the appointment of Chirfi Guindo to its board of directors.
“We are thrilled to welcome Chirfi to our board, bringing in yet another exceptionally talented and experienced biopharma leader to our team,” said CEO John Evans. “Chirfi’s strategic insight has been instrumental in driving innovation and expanding access to medicines, improving health outcomes for patients across both developed and emerging regions. His diverse expertise and visionary approach will be invaluable as we continue to drive toward sustainable growth and work to deliver potentially transformative one-time therapies to patients.”
About Chirfi Guindo
Chirfi Guindo is a seasoned executive in the pharmaceutical industry and has been a key leader at Merck for more than 25 years, where he held senior executive roles spanning global strategy, commercial operations, and leadership in healthcare solutions.
“I am honored to join Beam at such a transformative moment in its journey,” said Chirfi Guindo. “The company’s pioneering work in base editing has the potential to revolutionize our industry’s approach to genetic medicine, offering lifelong hope to patients facing conditions previously thought untreatable. I am eager to collaborate with the talented team at Beam to help amplify its groundbreaking science, build a leading company in genetic medicine, and help change the course of treatment for many serious diseases.”
Chirfi Guindo is a global product strategy and commercial expert and currently serves as CMO, of Human Health for Merck. He is responsible for leading the development and implementation of the company’s long-term strategy for its Human Health portfolio spanning oncology, vaccines, pharmaceutical, and pipeline products. Before this role, Chirfi Guindo was EVP and head of global product strategy and commercialization at Biogen. Before joining Biogen in 2017, Mr. Guindo began his Merck career in 1990 and spent more than 25 years in finance, sales, commercial, and marketing roles of increasing responsibility in the U.S. and globally. He led global marketing for Merck’s HIV portfolio and also led Merck’s Human Health businesses in Canada, the Netherlands, and South Africa. Guindo has been recognized for developing strong talent, forging innovative public-private partnerships, and elevating the profile of Merck as a patient-focused company.
Chirfi Guindo is a graduate of Ecole Centrale de Paris with a degree in Engineering and earned a Master of Business Administration from New York University’s Stern School of Management.
About Beam Therapeutics
Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform that includes a suite of gene editing and delivery technologies and is in the process of building internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable, le and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.
For more: https://beamtx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.